Answers are grounded in this paper and cite their sources.
Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1)--the one EBV antigen that is expressed in all EBV-associated malignancies--has long been thought to go undetected by the cell-mediated immune system. However, recent studies show that EBNA1 can be presented to both CD4+ and CD8+ T cells, making it a potential new target for immunotherapy of EBV-related cancers.
No takes yet. Share an insight, caveat, or question.
Christian Münz (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: